Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MRK, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Letermovir FDA approved Nov 2017 · Prevymis |
Kidney Transplant | Phase 4 · NCT07706166 | Not yet recruiting |
| Pembrolizumab FDA approved Sep 2014 · Keytruda |
Cervical Cancer | Phase 3 · NCT07216703 | Recruiting |
| Berahyaluronidase Alfa and Pembrolizumab FDA approved Sep 2025 · Keytruda Qlex |
Non-small Cell Lung Cancer | Phase 3 · NCT07190248 | Recruiting |
| Belzutifan FDA approved Aug 2021 · Welireg |
Pheochromocytoma/Paraganglioma | Phase 2 · NCT04924075 | Recruiting |
| Probenecid FDA approved Apr 1951 · Benemid (discontinued) |
Healthy | Phase 1 · NCT07840612 | Not yet recruiting |
| Fluorouracil | Colon Adenocarcinoma | Phase 3 · NCT06997497 | Recruiting |
| Androgen Deprivation Therapy (ADT) | Metastatic Hormone-Sensitive Prostate Cancer | Phase 3 · NCT04191096 | Terminated |
| Bomedemstat | Polycythemia Vera | Phase 2/3 · NCT07722611 | Recruiting |
| Calderasib (MK-1084) | Colon Adenocarcinoma | Phase 3 · NCT06997497 | Recruiting |
| Enlicitide Decanoate | Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 2/3 · NCT07058077 | Recruiting |
| Epacadostat | Head and Neck Cancer | Phase 3 · NCT03358472 | Completed |
| Intismeran Autogene | Non-small Cell Lung Cancer | Phase 3 · NCT07513376 | Recruiting |
| IV Tulisokibart | Ulcerative Colitis | Phase 3 · NCT06052059 | Active not recruiting |
| Anti-CD19/CD3 Bispecific Antibody MK-104 | B-cell Acute Lymphoblastic Leukemia | Phase 2/3 · NCT07570173 | Recruiting |
| MK-8748 | Diabetic Retinopathy | Phase 3 · NCT07705555 | Recruiting |
| Nab-paclitaxel | Breast Neoplasms | Phase 3 · NCT07060807 | Recruiting |
Also used in these trials (approved or third-party drugs, not MRK's own candidates): Acetaminophen, Aflibercept, Tocilizumab, Bevacizumab, Bevacizumab-Awwb, Blinatumomab, Capecitabine, Carboplatin, Cetuximab, Cisplatin, Dexamethasone, Diphenhydramine Hydrochloride.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MRK holds $8.4B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MRK files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MRK and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →